Role of cell-free DNA in haematological malignancies.
Cell-free DNA
leukaemia
liquid biopsy
myeloma
Journal
Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
13
12
2020
accepted:
17
01
2021
pubmed:
3
3
2021
medline:
11
11
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
Cell-free DNA (cfDNA) consists of fragments of double stranded DNA that are found in the circulation. They are released from the apoptosis of both normal haemopoietic cells and malignant cells. The use of cfDNA from easily accessible peripheral blood samples has created a new strategy in studying molecular genomics in haematological malignancies. Its use in diagnosis, prognosis and monitoring potentially precludes the need for repeated tissue samples, i.e., bone marrow biopsy or primary tissue biopsy. It also potentially provides a more comprehensive analysis of the disease as cfDNA are released from tumours from multiple sites of the body. While cfDNA research is still in its infancy, given its potential and the expansion in next generation sequencing (NGS) it has attracted a lot of attention in recent years. This review will focus on acute leukaemia, multiple myeloma and lymphoma and the potential diagnostic and prognostic implications of cfDNA, its role in response assessment and in detection of disease relapse.
Identifiants
pubmed: 33648721
pii: S0031-3025(21)00049-0
doi: 10.1016/j.pathol.2021.01.004
pii:
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
DNA
9007-49-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
416-426Informations de copyright
Copyright © 2021 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.